NASDAQ · NBIX
Healthcare · Drug Manufacturers - Specialty & Generic
$144.21
Up+$1.03 (+0.72%)
Updated Oct 6, 2026, 3:41 AM
SID Score
5.5/10
Composite research score
Smart Money
58/100
Neutral
Price performance · NBIX
1M range · 20 trading sessions · Daily adjusted prices
Prices through Oct 5, 2026
NBIX closed at $144.21 after 20 trading sessions, down 7.04% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 5, 2026 | $142.94 | $146.915 | $142.48 | $144.21 | 1.75M |
| Oct 2, 2026 | $141.41 | $144.56 | $140.36 | $143.18 | 1.65M |
| Oct 1, 2026 | $140.94 | $143.74 | $139.61 | $140.71 | 2.05M |
| Sep 30, 2026 | $138.33 | $142.91 | $137.63 | $141.84 | 1.85M |
| Sep 29, 2026 | $138.26 | $141.07 | $136.31 | $138.35 | 1.5M |
| Sep 28, 2026 | $137.76 | $140.59 | $136.78 | $140.44 | 1.43M |
| Sep 25, 2026 | $138.94 | $138.94 | $137.02 | $138.40 | 1.17M |
| Sep 24, 2026 | $138.54 | $140.63 | $137.00 | $138.94 | 1.17M |
| Sep 23, 2026 | $141.97 | $142.245 | $139.3167 | $139.49 | 1.75M |
| Sep 22, 2026 | $144.17 | $144.26 | $141.78 | $142.25 | 1.21M |
| Sep 21, 2026 | $146.15 | $146.26 | $143.45 | $143.96 | 1.39M |
| Sep 18, 2026 | $152.63 | $152.63 | $146.06 | $146.23 | 2.82M |
| Sep 17, 2026 | $151.14 | $152.065 | $149.71 | $151.83 | 1.18M |
| Sep 16, 2026 | $150.34 | $151.31 | $149.00 | $149.50 | 1.02M |
| Sep 15, 2026 | $156.70 | $156.70 | $149.15 | $150.02 | 1.33M |
| Sep 14, 2026 | $158.00 | $159.19 | $156.57 | $157.22 | 785.56K |
| Sep 11, 2026 | $157.195 | $159.67 | $156.12 | $156.22 | 890.88K |
| Sep 10, 2026 | $154.38 | $159.94 | $152.04 | $156.57 | 895.2K |
| Sep 9, 2026 | $154.61 | $155.55 | $152.38 | $155.14 | 1.05M |
| Sep 8, 2026 | $153.99 | $156.82 | $151.77 | $155.13 | 820.81K |
The latest Smart Investors Daily articles mentioning NBIX.
Company
Market Activity
Research & News
NBIX research
Company profile and research snapshot.
Neurocrine Biosciences Inc engages in the discovery, development, and commercialization of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 29, 2026 | UBS | Buy | — |
| Sep 11, 2026 | Morgan Stanley | Equal-Weight | — |
| Sep 8, 2026 | RBC Capital | Outperform | — |
| Sep 3, 2026 | Citigroup | Buy | — |
| Aug 13, 2026 | Morgan Stanley | Equal-Weight | — |
No generated briefing is available yet.
ChartMill · Oct 2, 2026
Neurocrine (NBIX) fits Affordable Growth with strong EPS growth, reasonable valuation, high profitability, and zero debt, backed by 98% gross margins.
Yahoo · Sep 30, 2026
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced research advancing understanding of Prader-Willi syndrome and expanding clinical and real-world evidence for VYKAT® XR (diazoxide choline) extended-release tablets will be presented at the Foundation for Prader-Willi Research (FPWR) 2026 Annual Research Symposium & Family Conference, taking place Oct. 7-10 in Philadelphia.
Benzinga · Sep 29, 2026
UBS analyst Ashwani Verma maintains Neurocrine Biosciences (NASDAQ:NBIX) with a Buy and lowers the price target from $231 to $214.
Yahoo · Sep 28, 2026
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that Eiry W. Roberts, M.D., who previously served as Neurocrine's Chief Medical Officer and currently serves as a Strategic Advisor, will rejoin the Company's executive management team as Chief Medical Officer (CMO), effective immediately. By mutual agreement, Sanjay Keswani, M.D., will depart the Company.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning NBIX.
